InsidersTradesSigma
Follow the Opexa Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 4 January 2016 (Attribution). Among the most active insiders: BARABE TIMOTHY C. The full history is accessible without an account.
Analysts rate Opexa Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
Opexa Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases, particularly multiple sclerosis. The company is listed on NASDAQ under the ticker OPXA.